At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Eltrombopag +1 moredrug
Likely dose
Eltrombopag 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
In Brief
A Phase 2 clinical trial evaluating Eltrombopag and Hypomethylating Agent (HMA) for Leukemia. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsGlaxoSmithKline, Novartis
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartOct 2013
Primary CompletionJan 2019
TodayJul 2026
First PostedJul 9, 2013
Enrollment StartOct 1, 2013
Primary CompletionJan 6, 2019
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 13.0 years ago
Interventions
Eltrombopagdrug
200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA)drug
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.